PROGNOSTIC ANALYSIS OF PD-1 ANTIBODY IN THE COMBINATION TREATMENT OF PRIMARY MALIGNANT MELANOMA OF ESOPHAGUS

Jiaxing Yu¹, Chongbiao Huang^{*, 2} 

¹Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China - ²Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China

Objective: To explore the effect of PD-1therapy on the prognosis of primary esophageal malignant melanoma, and to provide references for clinical treatment. 

Methods: A total of 14 patients with primary esophageal malignant melanoma, who were treated in Tianjin Medical University Cancer Hospital from 2013 to 2020, were collected. The treatment methods were counted, and the survival time was followed up. Kaplan-Meier curve was used to compare the effects of PD-1treatment on survival, and multivariate Cox proportional hazard regression was used to analyze the effects of different factors on survival. 

Results: The average age of 14 patients with primary esophageal malignant melanoma was 59 years old, of which 5 patients were treated by PD-1 and 9 patients were not. It was found that PD-1 treatment significantly prolonged the patient's survival based the Kaplan-Meier curve according to the follow-up of 14 patients (p=0.018). Furthermore, Multivariate Cox regression analysis proved that PD-1treatment is an independent factor affecting the survival and prognosis of patients (p=0.026) and whether surgery is not necessary (p=0.264).

Conclusion: PD-1 therapy can remarkably prolong the survival of patients with primary esophageal malignant melanoma.